Alberto Puccini, MD, Humanitas Research Hospital, Milan, Italy, discusses findings from the PROSIT study, which aimed to elucidate prognostic signature in patients with stage II colon cancer enrolled in the Phase III TOSCA trial (NCT00646607). In the trial, patients were randomized to receive three of six months of chemotherapy. A signature was identified among 17 differentially expressed genes independent of MSI status. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
